Assessment of safety profile of MGN1601 Treatment phase (12 weeks), extension phase (120 weeks, if applicable), plus 5 years follow-up [clinicaltrials_resource:ccc793eb2feedba6a1911a64f89c55c2]
Genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Assessment of safety profile of MGN1601 Treatment phase (12 weeks), extension phase (120 weeks, if applicable), plus 5 years follow-up [clinicaltrials_resource:ccc793eb2feedba6a1911a64f89c55c2]
Genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)
Bio2RDF identifier
ccc793eb2feedba6a1911a64f89c55c2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:ccc793eb2feedba6a1911a64f89c55c2
measure [clinicaltrials_vocabulary:measure]
Assessment of safety profile of MGN1601
time frame [clinicaltrials_vocabulary:time-frame]
Treatment phase (12 weeks), ex ...... cable), plus 5 years follow-up
description
Genetically modified allogenei ...... m loop immunomodulator (dSLIM)
identifier
clinicaltrials_resource:ccc793eb2feedba6a1911a64f89c55c2
title
Assessment of safety profile o ...... cable), plus 5 years follow-up
@en
type
label
Assessment of safety profile o ...... 793eb2feedba6a1911a64f89c55c2]
@en